Cecilia Karlsson
Overview
Explore the profile of Cecilia Karlsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daniels S, Karlsson C, Schrauwen P, Parker V
Trends Endocrinol Metab
. 2025 Feb;
PMID: 39934020
Identification of exendin-4 (a glucagon-like peptide 1 receptor agonist, GLP-1RA) in Gila monster venom may be regarded as one of the most serendipitous discoveries of recent times. GLP-1RAs are now...
2.
Shehadeh N, Galassetti P, Iqbal N, Karlsson C, Monyak J, Ostridge J, et al.
J Clin Endocrinol Metab
. 2024 Oct;
PMID: 39446459
Context: The T2NOW trial of dapagliflozin or saxagliptin versus placebo in pediatric patients with type 2 diabetes (T2D) demonstrated promising efficacy data for dapagliflozin and did not raise any safety...
3.
Carlsson L, Carlsson B, Jacobson P, Andersson-Assarsson J, Karlsson C, Kristensson F, et al.
Diabetes Obes Metab
. 2024 Oct;
27(1):238-246.
PMID: 39434432
Aims: Life expectancy is reduced in people with obesity and is further reduced in those with concomitant type 2 diabetes. The aim of the study was to assess whether a...
4.
Lukka P, Tang W, Hammarstedt A, Conrad T, Heijer M, Karlsson C, et al.
Clin Ther
. 2024 Aug;
46(9):717-725.
PMID: 39179458
Purpose: We evaluated the pharmacokinetics, safety, and tolerability of a fixed-dose combination (FDC) of dapagliflozin/sitagliptin versus individual component (IC) tablets in healthy Western and Korean participants. The combination of these...
5.
Karlsson C, Johnson L, Greasley P, Retterstol K, Hedberg J, Hall M, et al.
JAMA Surg
. 2024 Jul;
159(9):971-980.
PMID: 38959017
Importance: Roux-en-Y gastric bypass (RYGB) is associated with reduced cardiovascular (CV) risk factors, morbidity, and mortality. Whether these effects are specifically induced by the surgical procedure or the weight loss...
6.
Carlsson L, Carlsson B, Jacobson P, Karlsson C, Andersson-Assarsson J, Kristensson F, et al.
Int J Surg
. 2024 Jun;
110(10):6581-6590.
PMID: 38896851
Background: People with obesity and type 2 diabetes (T2D) have reduced life expectancy, partly explained by increased risk of cardiovascular diseases and cancer. Here, we examined whether 2-year diabetes remission...
7.
Kvitne K, Hjelmesaeth J, Hovd M, Sandbu R, Johnson L, Andersson S, et al.
Clin Pharmacol Ther
. 2024 May;
116(3):647-652.
PMID: 38771070
This article summarizes the lessons learned from the COCKTAIL study: an open, three-armed, single-center study including patients with obesity scheduled for treatment with Roux-en-Y gastric bypass (RYGB) or nonsurgical calorie...
8.
Sibeaux A, Newport C, Green J, Karlsson C, Engelmann J, Burt de Perera T
Commun Biol
. 2024 May;
7(1):578.
PMID: 38755224
Path integration is a powerful navigational mechanism whereby individuals continuously update their distance and angular vector of movement to calculate their position in relation to their departure location, allowing them...
9.
Shehadeh N, Barrett T, Galassetti P, Karlsson C, Monyak J, Iqbal N, et al.
NEJM Evid
. 2024 Feb;
2(12):EVIDoa2300210.
PMID: 38320500
BACKGROUND: Incidence of type 2 diabetes (T2D) in children and adolescents is increasing, but treatment options are limited. METHODS: This was a 26-week, phase 3 trial with a 26-week extension...
10.
Koshino A, Neuen B, Jongs N, Pollock C, Greasley P, Andersson E, et al.
Cardiovasc Diabetol
. 2023 Nov;
22(1):330.
PMID: 38017482
Background: This post-hoc analysis of the DELIGHT trial assessed effects of the SGLT2 inhibitor dapagliflozin on iron metabolism and markers of inflammation. Methods: Patients with type 2 diabetes and albuminuria...